Alkali burn to the eye: Protection using TNF-α inhibition

Cornea

Volumn 33, Issue 4, 2014, Pages 382-389

  Cade, Fabiano ^a   Paschalis, Eleftherios I ^a   Regatieri, Caio V ^a   Vavvas, Demetrios G ^a   Dana, Reza ^a   Dohlman, Claes H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

alkali burn; chemical injury; cornea; ganglion cell layer; inflammation

Indexed keywords

CD45 ANTIGEN; CYTOKINE; IMMUNOGLOBULIN G; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAUSTIC BURN; CONTROLLED STUDY; CORNEA INJURY; CORNEA NEOVASCULARIZATION; EYE PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA GANGLION CELL; RETINA INJURY; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIGENS, CD45; BURNS, CHEMICAL; CORNEAL DISEASES; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE BURNS; HYDROGEN-ION CONCENTRATION; IN SITU NICK-END LABELING; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED BALB C; RETINAL DISEASES; RETINAL GANGLION CELLS; SODIUM HYDROXIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896400360     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0000000000000071     Document Type: Article

References (20)

1. Schrage NF, Langefeld S, Zschocke J, et al. Eye burns: An emergency and continuing problem. Burns. 2000;26:689-699
2. Pfister RR. Chemical injuries of the eye. Ophthalmology. 1983;90:1246-1253
3. Cade F, Grosskreutz CL, Tauber A, et al. Glaucoma in eyes with severe chemical burn, before and after keratoprosthesis. Cornea. 2011;30:1322-1327
4. Tuft SJ, Shortt AJ. Surgical rehabilitation following severe ocular burns. Eye (Lond). 2009;23:1966-1971
5. Hoffart L, Matonti F, Conrath J, et al. Inhibition of corneal neovascularization after alkali burn: Comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone. Clin Experiment Ophthalmol. 2010;38:346-352
6. Liang L, Sheha H, Tseng SCG. Long-Term outcomes of keratolimbal allograft for total limbal stem cell deficiency using combined immunosuppressive agents and correction of ocular surface deficits. Arch Ophthalmol. 2009;127:1428-1434
7. Fagerholm P, Lisha G. Corneal stem cell grafting after chemical injury. Acta Ophthalmol Scand. 1999;77:165-169
8. Dohlman CH, Cade F, Pfister R. Chemical burns to the eye: Paradigm shifts in treatment. Cornea. 2011;30:613-614
9. T-Ataru CP, Purc-Area VL. Antiglaucoma pharmacotherapy. J Med Life. 2012;5:247-251
10. Kompa S, Redbrake C, Hilgers C, et al. Effect of different irrigating solutions on aqueous humour pH changes, intraocular pressure and histological findings after induced alkali burns. Acta Ophthalmol Scand. 2005;83:467-470
11. Miyamoto F, Sotozono C, Ikeda T, et al. Retinal cytokine response in mouse alkali-burned eye. Ophthalmic Res. 1998;30:168-171
12. Bagley DM, Casterton PL, Dressler WE, et al. Proposed new classification scheme for chemical injury to the human eye. Regul Toxicol Pharmacol. 2006;45:206-213
13. Nakazawa T, Kayama M, Ryu M, et al. Tumor necrosis factor-Alpha mediates photoreceptor death in a rodent model of retinal detachment. Invest Ophthalmol Vis Sci. 2011;52:1384-1391
14. Murakami Y, Miller JW, Vavvas DG. RIP kinase-mediated necrosis as an alternative mechanisms of photoreceptor death. Oncotarget. 2011;2: 497-509
15. Durrani K, Ahmed M, Foster CS. Adamantiades-Behcet disease: Diagnosis and current concepts in management of ocular manifestations. Compr Ophthalmol Update. 2007;8:225-233
16. Adán A, Sanmartí R, Burés A, et al. Successful treatment with infliximab in a patient with diffuse subretinal fibrosis syndrome. Am J Ophthalmol. 2007;143:533-534
17. Weiss K, Rieger R, Keitzer R, et al. Successful infliximab treatment of posterior scleritis in a 13-year-old child refractory to other immunosuppressive therapy. Graefes Arch Clin Exp Ophthalmol. 2007;245: 1735-1737
18. Japiassú RM, Brasil OFM, Cunha AL, et al. Regression of vasoproliferative tumor with systemic infliximab. Ophthalmic Surg Lasers Imaging. 2008;39:348-349
19. Roh M, Zhang Y, Murakami Y, et al. Etanercept, a widely used inhibitor of tumor necrosis factor-A (TNF-A), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One. 2012;7:e40065
20. Ferrari G, Bignami F, Giacomini C, et al. Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring. Invest Ophthalmol Vis Sci. 2013;54:1680-1688